MABox
CIBA


  • An estimated 45,220 Americans were diagnosed with pancreatic cancer in the U.S. in 2013, and 38,460 died from the disease. 
     
  • Pancreatic cancer is one of the few cancers for which survival has not improved substantially over nearly 40 years. 
     
  • Pancreatic cancer is the 4th leading cause of cancer-related death in the United States.
     
  • Pancreatic cancer has the highest mortality rate of all major cancers. 94% of pancreatic cancer patients will die within five years of diagnosis – only 6% will survive more than five years. 75% of patients die within the first year of diagnosis.
     
  • The average life expectancy after diagnosis with metastatic disease is just three to six months.
     
  • Few risk factors for developing pancreatic cancer are defined. Family history of the disease, smoking, age, and diabetes are risk factors.
     
  • Pancreatic cancer may cause only vague symptoms that could indicate many different conditions within the abdomen or gastrointestinal tract.
     
  • Symptoms include pain (usually abdominal or back pain), weight loss, jaundice (yellowing of the skin and eyes), loss of appetite, nausea, changes in stool, and diabetes.
     
  • Treatment options for pancreatic cancer are limited. Surgical removal of the tumor is possible in only approximately 15% of patients diagnosed with pancreatic cancer. Chemotherapy or chemotherapy together with radiation is typically offered to patients whose tumors cannot be removed surgically. Only three drugs are FDA-approved for the treatment of pancreatic cancer: fluorouracil (5-FU), gemcitabine (Gemzar®), and erlotinib (Tarceva®).
     
  • Pancreatic cancer is a leading cause of cancer death largely because there are no detection tools to diagnose the disease in its early stages when surgical removal of the tumor is still possible.
     
  • The National Cancer Institute (NCI) spent an estimated $89.4 million on pancreatic cancer research in 2009. This represented a mere 2% of the NCI’s approximate $5 billion cancer research budget for that year.

Home | About CIBA | About Michael | Thanks | Donate/Sponsor | Contact Us
2017 Abelon Walk for Pancreatic Cancer